Last reviewed · How we verify
NCT05034458
Diet in Pediatric Crohn´s Disease Treated With Biologics
NA trial testing Crohn's disease exclusion diet in Crohn's Disease in 30 participants. Completed in 20 June 2023.
1 June 2023
Quick facts
| Lead sponsor | Hospital Italiano de Buenos Aires |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 14 May 2021 |
| Primary completion | 1 June 2023 |
| Estimated completion | 20 June 2023 |
| Sites | 1 location across Argentina |
Drugs / interventions tested
- Crohn's disease exclusion diet
Conditions studied
- Crohn's Disease — all drugs for Crohn's Disease →
Sponsor
Hospital Italiano de Buenos Aires
Who can join
Adults 1 Month to 18, any sex, with Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cded in remission patients with high calprotectin
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of adjuvant Crohn's disease exclusion diet plus enteral nutrition in asymptomatic pediatric Crohn's disease having biochemical activity: A randomized, pilot study.
Arcucci MS, Menendez L, Orsi M, Gallo J, et al · · 2024 · cited 8× · PMID 37610564 · DOI 10.1007/s12664-023-01416-x
Verify or expand the search:
- PubMed search for NCT05034458
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Crohn's Disease
Currently open trials in the same condition.
- NCT07273188 — 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease · EARLY_PHASE1 · recruiting
- NCT07184944 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
- NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
- NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
- NCT07184931 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting
Other Hospital Italiano de Buenos Aires trials
Trials by the same sponsor.
- NCT07397416 — Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Cont · NA · not yet recruiting
- NCT07167173 — Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis · not yet recruiting
- NCT06683781 — Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06609798 — Ultrasound Assessment During Weaning from Mechanical Ventilation · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05034458 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Italiano de Buenos Aires
- Last refreshed: 25 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05034458.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing